1. Kesimpta MS Webinar

Kesimpta MS Webinar

Click here for Product Information

Treating and Managing MS with Kesimpta®▼

Novartis MS Meeting featuring
Dr. Wallace Brownlee, National Hospital for Neurology & Neurosurgery, London
Saturday 19th November 2022

 
Reference:
  1. KESIMPTA SPC available at www.medicines.ie Last accessed November 2022
Rate this content: 
No votes yet
November 2022 | IE252765
Print
▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.